Medtronic's Hugo Robot Enters the Ring Against Intuitive Surgical

Medtronic (MDT) has officially entered the U.S. robotic surgery market after receiving FDA approval for its Hugo platform for urologic procedures in December 2025. This marks the end of Medtronic's years-long wait on the sidelines of a market pioneered and dominated by Intuitive Surgical (ISRG) and its da Vinci system.

The approval allows Hugo to be used for specific surgeries like prostatectomies, representing a potential slice of the approximately 230,000 such procedures performed annually in the U.S. Shortly after the approval, doctors at the Cleveland Clinic successfully completed the first U.S. procedure with the system.

This move directly challenges Intuitive Surgical, which has enjoyed a near-monopoly for over two decades. The market itself is projected to explode, growing from $13.8 billion last year to an estimated $63.7 billion by 2035, making Medtronic's entry timely.

However, Hugo's U.S. approval is currently limited to urology. While Medtronic has just applied to expand its use to gynecologic and general surgeries, the da Vinci system is already approved and routinely used for these broader categories, giving Intuitive a significant procedural advantage.

This development matters because it introduces real competition into a high-growth, high-margin market. For years, Intuitive Surgical's dominance allowed it to command premium pricing and build deep, sticky relationships with hospitals. Medtronic's entry could pressure margins and force innovation, benefiting healthcare providers and patients.

For Intuitive Surgical, the threat is real but not immediate. The company's moat is incredibly wide, with over 11,395 da Vinci systems installed globally. Hospitals invest heavily upfront and in ongoing training and supplies, making switching costs high. Intuitive continues to place hundreds of new systems each quarter, widening the gap.

For Medtronic, success doesn't require dethroning the king. As a diversified healthcare giant with $38.8 billion in revenue, it can afford to be patient. Hugo is already in over 35 countries, and procedure volumes are growing two to three times faster than the market, albeit from a small base.

The ultimate prize is the vast untapped market. Only about 5% of global surgeries are robot-assisted today. Both companies can grow substantially as adoption increases. Medtronic's goal is to capture a meaningful share of this expansion, not necessarily to overtake Intuitive's installed base lead, which may be insurmountable in the near term.